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The observation that Akt inhibition does not significantly alter metabolism and proliferation of CD8 T cells, but promotes a transcriptional program that drives memory may be therapeutically important because response to ACT not only correlates with features of immunologic memory, but also absolute number of adoptively-transferred TIL. We were therefore interested in exploring whether inhibition of Akt could promote features of memory in tumor-infiltrating cytotoxic T cells without significantly modulating metabolism or cell proliferation.
To evaluate this, we expanded TIL in the presence of a well-characterized allosteric inhibitor of Akt (18) that has previously been used in murine cytotoxic T cells (10) . We found that human TIL cultured in Akt inhibitor demonstrate enhanced features of immunologic memory that correlate with improved long-term persistence after adoptive transfer. Although Akt inhibition did not compromise TIL proliferation, we were somewhat surprised to find that it significantly modulated the metabolic profile of TIL. Importantly, in a murine model of ACT, we show that Akt inhibition improved anti-tumor immunity of cytotoxic T cells. Taken together, these findings support the use of pharmacologic approaches to enhance cellintrinsic qualities of TIL that may potentially augment anti-tumor immunity and improve the efficacy of cell-based immunotherapy for advanced cancer (supplemental Figure 1) .
Patients, materials, and methods
Patient cell samples. Human cells used in this study were isolated from patients with metastatic melanoma receiving treatment under institutional review board-approved clinical protocols (NCT01319565 or NCT00670748) in the Surgery Branch of the National Cancer Institute. Informed consent was obtained from all subjects. Tumor-infiltrating cytotoxic T lymphocyte (TIL) cultures were established as previously described (19) . Briefly, tumor fragments or digests were cultured in 6000 IU/mL IL-2 for 2 weeks, and subsequently expanded with a rapid expansion protocol using 30 ng/mL OKT3 (anti-CD3) antibody (Miltenyi Biotech) and 6000 IU/mL IL-2 in the presence of irradiated (50 Gy) allogeneic feeder cells at a 200:1 ratio of feeder cells to TIL. TIL were harvested for myriad assays 30 5 days after initiation of culture including FACS analysis, coculture with tumor targets, microarray analysis, adoptive-transfer into NSG mice, and metabolomic analysis.
Mice and tumor lines. Thy1.1 and Ly5.1 Pmel-1TCR-transgenic (Pmel) mice have been described previously (20) . NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice and C57BL/6 (B6) mice were purchased from The Jackson Laboratory. Mice were housed in the National Institutes of Health (NIH) Clinical
Research Center vivarium and maintained in compliance with the NIH Animal Care and Use Committee.
Mice were excluded from analysis if less than 6 weeks old and not age-and gender-matche d with experimental cohort. Mice were randomized to treatment group and investigators blinded when measuring outcomes of: tumor size, survival after adoptive transfer, and histopathological analysis. Splenocytes from Pmel mice were stimulated with hgp100 25-33 peptide (1µM) and 1000 IU/mL recombinant human interleukin-2 (rhIL-2; Novartis) in the presence or absence of 1µM AktI-1/2 (Akti; Calbiochem) and CD8 + T cells were harvested at day 5. Secondary stimulation was performed using peptide-pulsed irradiated B6 feeder cells. The human SK23 melanoma tumor line and B16F10 tumor line (B16) was obtained from the National Cancer Institute tumor repository and tested for mycoplasma contamination.
Gene expression analysis and cytokine production assays. For real-time reverse-transcriptionpolymerase chain reaction (RT-PCR), RNA was extracted with RNeasy Kits (QIAGEN) and cDNA was generated using High Capacity RNA-to-cDNA Kits (Applied Biosystems). Real time RT-PCR was performed on a CFX96 thermal cycler (Bio-Rad) using primer/probe sets for indicated genes and ACTB (Applied Biosystems). For cytokine production assays, coculture of TIL with autologous tumor was performed and supernatants assessed for the presence of gamma-interferon (IFN-γ) by enzyme-linked immunosorbent assay (ELISA) in accordance with manufacturer's protocol.
Adoptive cell transfer. Tumor therapy was performed as described previously (20 
Results

Inhibition of Akt promotes expression of CD62L in human tumor-specific cytotoxic lymphocytes without compromising cell expansion
Akt is known to control lymphoid homing behavior of T cells through regulation of the adhesion molecule CD62L (10) . To test whether Akt inhibition affects expression of CD62L on the surface of human TIL, we used a well-characterized allosteric inhibitor of all three isoforms of Akt (hereafter Akti) (18) . We first sought to confirm whether Akti inhibits phosphorylation of Akt and downstream targets in human TIL. When measured at acute time points after TCR stimulation, we found that phosphorylation of Akt is inhibited at both the serine 473 and threonine 308 residues, resulting in decreased phosphorylation of its downstream substrates ribosomal protein S6 ( Figure 1A ) and glycogen synthase kinase 3 beta (GSK3β) (supplemental Figure 2) . We then isolated TIL from three patients with metastatic melanoma as previously described (19) , expanded them at clinical-scale in the presence or absence of Akti, and 9 measured surface expression of CD62L on CD4 + and CD8 + T cells. We found that Akti-expanded TIL had significantly increased expression of CD62L ( Figure 1B) . Strikingly, however, we did not observe an effect of Akt inhibition on the expansion of TIL ( Figure 1C ). Finally, we sought to determine if Akt inhibition compromises tumor-specificity or capacity to release interferon-gamma (IFNγ) when cocultured with autologous tumor cells. Akti-treated TIL released similar levels of IFNγ compared to conventional TIL that was restricted in an MHC class I-dependent manner ( Figure 1D ). Thus, pharmacological inhibition of Akt enables expansion of TIL expressing elevated levels of CD62L without affecting their expansion or capacity to release IFNγ upon recognition of tumor targets.
Inhibition of Akt in human tumor-infiltrating lymphocytes (TIL) promotes a transcriptional signature of memory T cells
Expression of CD62L distinguishes antigen-experienced cells with a central memory phenotype (22) . In addition to their lymphoid homing capacity, these cells exhibit enhanced capacity for cell survival and proliferation (5, (23) (24) . Given elevated expression of CD62L on the surface of Akti-expanded TIL, we 
Akt inhibition is associated with enhanced fatty-acid oxidation in human cytotoxic TIL
There is increasing evidence that memory T cells have metabolic qualities such as reduced glycolysis (26) and enhanced mitochondrial fatty acid oxidation (FAO) that support long-term survival and effector function (27) . 
